{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:51:00Z","timestamp":1774536660455,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral iron preparations are used as first-line treatment for iron deficiency anemia (IDA), but their gastrointestinal side effects prevent patients from appropriate adherence. We recently conducted a randomized, double-blind, phase 3 non-inferiority study to evaluate the efficacy and safety of two dosages of ferric citrate hydrate (FC) compared with sodium ferrous citrate (SF) in patients with IDA. FC at both 500 and 1000\u00a0mg\/day was non-inferior to SF at 100\u00a0mg\/day in terms of the change in the hemoglobin concentration at Week 7 from baseline. Logistic regression analysis suggested that the cumulative proportion of patients who achieved the target hemoglobin concentration (\u2265\u200913.0\u00a0g\/dL in male patients and\u2009\u2265\u200912.0\u00a0g\/dL in female patients) at Week 7 was highest among those treated with FC at 1000\u00a0mg\/day, followed by SF at 100\u00a0mg\/day and FC at 500\u00a0mg\/day. Both dosages of FC were well tolerated in patients with IDA. The incidences of nausea and vomiting were significantly lower in the FC treatment groups than in the SF group. In conclusion, FC has potential to be an oral iron preparation with sufficient efficacy for the treatment of IDA and a lower risk of nausea and vomiting.<\/jats:p>","DOI":"10.1007\/s12185-021-03123-9","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T04:12:40Z","timestamp":1615781560000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study"],"prefix":"10.1007","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-9126","authenticated-orcid":false,"given":"Norio","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojo","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hanaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"3123_CR1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832\u201343.","journal-title":"N Engl J Med"},{"key":"3123_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","volume":"123","author":"NJ Kassebaum","year":"2014","unstructured":"Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systemic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615\u201324.","journal-title":"Blood"},{"key":"3123_CR3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2214-109X(13)70001-9","volume":"1","author":"GA Stevens","year":"2013","unstructured":"Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995\u20132011: a systematic analysis of population-representative data. Lancet Glob Health. 2013;1:e16-25.","journal-title":"Lancet Glob Health"},{"key":"3123_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","volume":"142","author":"MW Hentze","year":"2010","unstructured":"Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24\u201338.","journal-title":"Cell"},{"key":"3123_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.12669\/pjms.323.9799","volume":"32","author":"C Gereklioglu","year":"2016","unstructured":"Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32:604\u20137.","journal-title":"Pak J Med Sci"},{"key":"3123_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0277-9536(94)90135-X","volume":"39","author":"R Galloway","year":"1994","unstructured":"Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med. 1994;39:381\u201390.","journal-title":"Soc Sci Med"},{"key":"3123_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gft483","volume":"29","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29:1053\u201360.","journal-title":"Nephrol Dial Transplant"},{"key":"3123_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000366482","volume":"128","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Hirakata H. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. Nephron Clin Pract. 2014;128:135\u201340.","journal-title":"Nephron Clin Pract"},{"key":"3123_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543\u201352.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3123_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-019-01125-w","volume":"79","author":"T Ganz","year":"2019","unstructured":"Ganz T, Bino A, Salusky IB. Mechanism of action and clinical attributes of Auryxia\u00ae (ferric citrate). Drugs. 2019;79:957\u201368.","journal-title":"Drugs"},{"key":"3123_CR11","first-page":"437","volume":"98","author":"JB Lanier","year":"2018","unstructured":"Lanier JB, Park JJ, Callahan RC. Anemia in older adults. Am Fam Physician. 2018;98:437\u201342.","journal-title":"Am Fam Physician"},{"key":"3123_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MOG.0b013e32831ef1cd","volume":"25","author":"SF Clark","year":"2009","unstructured":"Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009;25:122\u20138.","journal-title":"Curr Opin Gastroenterol"},{"key":"3123_CR13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671\u20136.","journal-title":"Haematologica"},{"key":"3123_CR14","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69061.x","volume":"69","author":"IC Macdougall","year":"1999","unstructured":"Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61\u20136.","journal-title":"Kidney Int Suppl"},{"key":"3123_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0165-6147(88)90106-X","volume":"9","author":"PL Andrews","year":"1988","unstructured":"Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988;9:334\u201341.","journal-title":"Trends Pharmacol Sci"},{"key":"3123_CR16","first-page":"131","volume":"248","author":"Y Torii","year":"1993","unstructured":"Torii Y, Mutoh M, Saito H, Matsuki N. Involvement of free radicals in cisplatin-induced emesis in Suncus murinus. Eur J Pharmacol. 1993;248:131\u20135.","journal-title":"Eur J Pharmacol"},{"key":"3123_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2012.01.046","volume":"684","author":"C Rojas","year":"2012","unstructured":"Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1\u20137.","journal-title":"Eur J Pharmacol"},{"key":"3123_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2190001","volume":"219","author":"B Halliwell","year":"1984","unstructured":"Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984;219:1\u201314.","journal-title":"Biochem J"},{"key":"3123_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.prp.2008.12.013","volume":"205","author":"X Zhang","year":"2009","unstructured":"Zhang X, Ouyang J, Wieczorek R, DeSoto F. Iron medication-induced gastric mucosal injury. Pathol Res Pract. 2009;205:579\u201381.","journal-title":"Pathol Res Pract"},{"key":"3123_CR20","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2147\/DDDT.S81863","volume":"9","author":"JE Toblli","year":"2015","unstructured":"Toblli JE, Cao G, Angerosa M. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats. Drug Des Devel Ther. 2015;9:2585\u201397.","journal-title":"Drug Des Devel Ther"},{"key":"3123_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000348805","volume":"37","author":"A Iida","year":"2013","unstructured":"Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37:346\u201358.","journal-title":"Am J Nephrol"},{"key":"3123_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1292\/jvms.19-0641","volume":"82","author":"A Iida","year":"2020","unstructured":"Iida A, Matsushita M, Ohta T, Yamada T. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats. J Vet Med Sci. 2020;82:379\u201386.","journal-title":"J Vet Med Sci"},{"key":"3123_CR23","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814\u20136.","journal-title":"Bone"},{"key":"3123_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Runbin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323:432\u201343.","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1007\/s12185-024-03739-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03123-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T07:20:29Z","timestamp":1709709629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3123"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03123-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-024-03739-7","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-024-03739-7","URL":"https:\/\/doi.org\/10.1007\/s12185-024-03739-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was performed as a Phase III study funded by Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. Komatsu received personal fees from Japan Tobacco Inc. during the conduct of the study. Arita, Mitsui, Nemoto and Hanaki are employees of Japan Tobacco Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}